'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions
SAN ANTONIO — Well behind Novo Nordisk and Eli Lilly in the obesity race, AstraZeneca came to this year’s ObesityWeek with three assets in hand …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
